Gene-dosage effect of Pfkfb3 on monocyte/macrophage biology in atherosclerosis.

ABSTRACT:

Background and purpose

Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models. However, genetic studies elucidating the role of Pfkfb3 in atherogenesis need to be conducted to validate pharmacological findings and to unveil potential pharmacological side effects.

Experimental approach

Apoe^-/- mice with global heterozygous or myeloid cell-specific Pfkfb3 deficiency were fed a Western diet (WD), after which atherosclerosis development was determined. Monocyte subsets in atherosclerotic mice and patients were examine

SUBMITTER: Guo S 

PROVIDER: S-EPMC10420406 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature